Searchable abstracts of presentations at key conferences in endocrinology

ea0016p613 | Reproduction | ECE2008

Growth hormone improves semen volume, sperm count and motility in men with idiopathic normogonadotropic infertility

Kalra Sanjay , Kalra Bharti , Sharma Amit

Objective: The aim of this exploratory study was to assess the effect of growth hormone on semen parameters in men with primary infertility and normogonadotropic idiopathic oligoasthenospermia.Method: This study was performed as a prospective, open- label, non-randomized observational study in a private practice in fourteen men, aged 26 to 35, with normogonadotropic idiopathic oligoasthenospermia. Growth hormone 1.5 IU/day was administered for 6 months a...

ea0016p193 | Diabetes and cardiovascular diseases | ECE2008

Use of three dose premixed aspart: clinical correlates

Kalra Sanjay , Kalra Bharti , Sharma Amit , Chhabra Bhavika

Objective: Premixed aspart is being used in once, twice and thrice-daily regimes in persons with diabetes. This study was designed as a cross-sectional, observational study to assess the need for three-dose premixed aspart in different subsets of subjects with type 1 and type 2 diabetes attending an endocrine OPD.Methods: Records of 200 consecutive patients receiving premixed insulin were assessed to determine the frequency of insulin dosage and its clin...

ea0048oc2 | Oral Communications | SFEEU2017

Cardiac risk stratification in bariatric patients: a step to minimise heartache

Younus Hafsa , Sharma Amit , Majid Kiran , Sarma Diwakar , Chakravartty Saurav , Patel Ameet G.

Introduction: Morbid obesity has serious associated co morbidities and is an independent risk factor for ischaemic heart disease. Obesity together with low functional status and exercise tolerance makes pre-operative cardiac assessment difficult and patients with few cardiac risk factors are often referred for cardiac assessment. This can not only be burdensome to services and prolongs waiting times for surgery but can also cause patient anxiety and poor compliance.<p clas...

ea0022p280 | Diabetes | ECE2010

Knowledge, attitudes and practices of type 1 diabetes patients regarding complementary and alternative medicine (CAM)

Kalra Sanjay , Kumar Satish , Kalra Bharti , Agrawal Navneet , Sharma Amit , Prusty Vinay

This multicentric, observational, non interventional study of patients with type 1 diabetes observed their knowledge, attitudes and practices regarding complementary and alternative medicine (CAM), including nutraceuticals. One hundred and thirty-five subjects with type 1 diabetes, aged <20 years, and their parents were surveyed using a structured pre-tested questionnaire.The cohort included 65.92% boys, 37.04% rural dwellers and 31.85% patients with...

ea0099p471 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Mandodari Rajurkar Dr , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis aimed to assess efficacy and safety of triple-drug FDC versus (vs) two-drug combination in T2DM Indian patients with HbA1c 9%-11%.<p class...

ea0099ep337 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Rajurkar Mandodari , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis assessed efficacy and safety of triple-drug FDC vs (vs) two-drug combination in T2DM Indian patients aged <45 years and 45-65 years.<p...